Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

551.00 -1.86 (-0.34%)
Streaming Delayed Price Updated: 1:04 PM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Vertex Reports Second Quarter 2026 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
From AbCellera Biologics Inc.
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Acquire Crinetics Pharmaceuticals
From Vertex Pharmaceuticals Incorporated and Crinetics Pharmaceuticals, Inc.
Via Business Wire
News headline image
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Participate in Upcoming May Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Reports First Quarter 2026 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Announce First Quarter 2026 Financial Results on May 4th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST
Via ACCESS Newswire
News headline image
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Participate in Upcoming March Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
Issued on behalf of Avant Technologies Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
Issued on behalf of Avant Technologies Inc. 
From USA News Group
Via GlobeNewswire
News headline image
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Reports Third Quarter 2025 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.